Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Opdivo Snatches Back Top Spot in Japan Sales Ranking in September: Encise
October 6, 2023
- Sawai Bags CML Nod for Sprycel Generic
October 5, 2023
- JCR to Explore Best Opportunities for Overseas Alliance on JR-171: Exec
October 5, 2023
- Manlio Florenzano Takes Helm of Sandoz Japan as Spin-Off Completes
October 5, 2023
- Nippon Kayaku Buys Stake in Adlai to Drive Cancer Drug Collab
October 5, 2023
- CSL/Alfresa Roll Out Home Delivery Service of Hemophilia Drugs
October 4, 2023
- Takeda to Pull Lung Cancer Med Exkivity in US after Trial Miss
October 4, 2023
- Drug Makers Discontinue Sales of Alesion Dry Syrup, Generic Versions
October 3, 2023
- Meiji Launches Japan PIII of mRNA COVID Shot for BA.4/5 Strain
October 3, 2023
- Chugai Embraces ChatGPT to Streamline Internal Tasks, Search Research Papers and More
October 3, 2023
- Tarlige Tops July Rep Promotion Ranking, Takes Back Crown from Mounjaro for GPs: Intage
October 3, 2023
- Kyorin to Cut Non-Sales Jobs through Voluntary Buyout
October 3, 2023
- FDA Gives Thumbs-Down for MEDRx/DWTI’s Lidocaine Patch
October 3, 2023
- Nihon Servier Launches Blood Cancer Med Oncaspar in Japan
October 3, 2023
- Chugai’s NMOSD Drug Enspryng Now Available in Taiwan
October 3, 2023
- Izumi Yoshida Named Japan President of CSL Behring
October 2, 2023
- GSK, Kyushu University Forge Oncology Partnership
October 2, 2023
- Takeda Seeks Japan Nod for Hutchmed’s Colorectal Cancer Drug
October 2, 2023
- Pfizer Japan Files New Dosage Forms for XBB.1.5 COVID Vaccine
October 2, 2023
- Medipal/JCR to Pair Up for Mucopolysaccharidosis Type IIIB Drug
September 29, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…